Last reviewed · How we verify
YR001 Dose A on middle body surface area
YR001 Dose A on middle body surface area is a Small molecule drug developed by Hangzhou Yirui Pharmaceutical Technology Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | YR001 Dose A on middle body surface area |
|---|---|
| Sponsor | Hangzhou Yirui Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YR001 Dose A on middle body surface area CI brief — competitive landscape report
- YR001 Dose A on middle body surface area updates RSS · CI watch RSS
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd portfolio CI
Frequently asked questions about YR001 Dose A on middle body surface area
What is YR001 Dose A on middle body surface area?
YR001 Dose A on middle body surface area is a Small molecule drug developed by Hangzhou Yirui Pharmaceutical Technology Co., Ltd.
Who makes YR001 Dose A on middle body surface area?
YR001 Dose A on middle body surface area is developed by Hangzhou Yirui Pharmaceutical Technology Co., Ltd (see full Hangzhou Yirui Pharmaceutical Technology Co., Ltd pipeline at /company/hangzhou-yirui-pharmaceutical-technology-co-ltd).
What development phase is YR001 Dose A on middle body surface area in?
YR001 Dose A on middle body surface area is in Phase 1.